Status:
COMPLETED
Rifabutin-containing Triple Therapy for Treatment of Helicobacter Pylori
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Conditions:
Helicobacter Pylori Infection
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Rifabutin has good chemical stability and low drug resistance rate in acidic gastric environment. Therefore, it is often used in combination with amoxicillin proton pump inhibitor for the rescue treat...
Eligibility Criteria
Inclusion
- ability and willingness to participate in the study and to sign and give informed consent
- Confirmed H. pylori infection and with previous treatment experience
Exclusion
- Less than 18 years old
- With previous gastric surgery
- Previous history of tuberculosis
- Major systemic diseases
- Pregnancy or lactation
- Allergy to any of the study drugs Administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion
Key Trial Info
Start Date :
May 7 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 30 2022
Estimated Enrollment :
413 Patients enrolled
Trial Details
Trial ID
NCT04879992
Start Date
May 7 2021
End Date
October 30 2022
Last Update
November 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, China, 200127